TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET 22
1.4 LIMITATIONS 23
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCTS LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET APPLICATION COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 INTERNATIONAL STANDARDS 41
4.2 REGIONAL STANDARDS 41
4.3 MARKET VIEWPOINT OF KEY OPINION LEADERS 41
4.4 EXPECTATIONS OF FUTURE MARKET SCENARIOS 41
4.5 FINDINGS AND REGIONAL TRENDS 42
4.6 COMPETITIVE GROUPING 43
5 COUNTRY WISE- NO OF PROCEDURES 53
5.1 NORTH AMERICA 54
5.2 EUROPE 55
5.3 ASIA-PACIFIC 56
5.4 SOUTH AMERICA 57
5.5 MIDDLE EAST AND AFRICA 58
6 REGULATION 59
6.1 UNITED STATES 59
6.2 EUROPE 60
6.3 CHINA 61
6.4 AUSTRALIA 61
7 MARKET OVERVIEW 63
7.1 DRIVERS 65
7.1.1 INCREASE IN THE GERIATRIC POPULATION 65
7.1.2 RISE IN INCIDENCE OF GLAUCOMA ACROSS THE WORLD 65
7.1.3 GOVERNMENT INITIATIVES TO INCREASE AWARENESS ABOUT THE PREVENTION OF BLINDNESS 66
7.1.4 GROWTH IN POPULARITY OF MINIMALLY INVASIVE SURGERY ACROSS THE GLOBE 66
7.2 RESTRAINTS 67
7.2.1 INADEQUATE REIMBURSEMENT SCENARIO 67
7.2.2 STRINGENT REGULATIONS FOR MIGS DEVICES 67
7.2.3 HIGH COST OF SURGICAL PROCEDURES 67
7.3 OPPORTUNITIES 68
7.3.1 RAPID TRANSITION FROM GLAUCOMA MEDICATION TO MINIMALLY INVASIVE GLAUCOMA SURGERIES 68
7.3.2 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCT 68
7.4 CHALLENGES 69
7.4.1 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 69
7.4.2 RISKS ASSOCIATED WITH THE MICRO INVASIVE GLAUCOMA SURGERY 70
8 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY PRODUCT 71
8.1 OVERVIEW 72
8.2 MIGS STENTS 75
8.3 MIGS SHUNTS 75
8.4 OTHERS 76
9 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY TARGET 77
9.1 OVERVIEW 78
9.2 TRABECULAR MESHWORK 81
9.3 SUPRACHOROIDAL SPACE 81
9.4 SUBCONJUNCTIVAL FILTRATION 82
9.5 REDUCING AQUEOUS PRODUCTION 83
10 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY TYPE 84
10.1 OVERVIEW 85
10.2 GLAUCOMA IN CONJUNCTION WITH CATARACT 88
10.3 STAND-ALONE GLAUCOMA 88
11 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY END USER 90
11.1 OVERVIEW 91
11.2 HOSPITAL 94
11.3 OPHTHALMOLOGY CLINICS 94
11.4 AMBULATORY SURGERY CENTERS (ASCS) 95
11.5 OTHERS 96
12 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY DISTRIBUTION CHANNEL 97
12.1 OVERVIEW 98
12.2 DIRECT TENDER 101
12.3 RETAIL SALES 101
13 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY REGION 103
13.1 ASIA-PACIFIC 104
13.1.1 CHINA 110
13.1.2 JAPAN 112
13.1.3 INDIA 114
13.1.4 SOUTH KOREA 116
13.1.5 AUSTRALIA 118
13.1.6 SINGAPORE 120
13.1.7 THAILAND 122
13.1.8 MALAYSIA 124
13.1.9 INDONESIA 126
13.1.10 PHILIPPINES 128
13.1.11 REST OF ASIA-PACIFIC 130
14 ASIA PACIFIC MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET: COMPANY LANDSCAPE 131
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 131
15 SWOT ANALYSIS 132
16 COMPANY PROFILE 133
16.1 GLAUKOS CORPORATION 133
16.1.1 COMPANY SNAPSHOT 133
16.1.2 REVENUE ANALYSIS 133
16.1.3 COMPANY SHARE ANALYSIS 134
16.1.4 PRODUCT PORTFOLIO 134
16.1.4.1 RECENT DEVELOPMENT 134
16.2 ALCON INC. 135
16.2.1 COMPANY SNAPSHOT 135
16.2.2 REVENUE ANALYSIS 135
16.2.3 COMPANY SHARE ANALYSIS 136
16.2.4 PRODUCT PORTFOLIO 136
16.2.4.1 RECENT DEVELOPMENTS 137
16.3 ABBVIE INC. 138
16.3.1 COMPANY SNAPSHOT 138
16.3.2 REVENUE ANALYSIS 138
16.3.3 COMPANY SHARE ANALYSIS 139
16.3.4 PRODUCT PORTFOLIO 139
16.3.4.1 RECENT DEVELOPMENT 139
16.4 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON) 140
16.4.1 COMPANY SNAPSHOT 140
16.4.2 REVENUE ANALYSIS 140
16.4.3 COMPANY SHARE ANALYSIS 141
16.4.4 PRODUCT PORTFOLIO 141
16.4.4.1 RECENT DEVELOPMENT 141
16.5 SANTEN PHARMACEUTICAL CO., LTD. 142
16.5.1 COMPANY SNAPSHOT 142
16.5.2 REVENUE ANALYSIS 142
16.5.3 COMPANY SHARE ANALYSIS 143
16.5.4 PRODUCT PORTFOLIO 143
16.5.4.1 RECENT DEVELOPMENTS 143
16.6 BELKIN VISION, ISRAEL 145
16.6.1 COMPANY SNAPSHOT 145
16.6.2 PRODUCT PORTFOLIO 145
16.6.3 RECENT DEVELOPMENT 145
16.7 BVI 146
16.7.1 COMPANY SNAPSHOT 146
16.7.2 PRODUCT PORTFOLIO 146
16.7.2.1 RECENT DEVELOPMENTS 147
16.8 ELLEX INC. 148
16.8.1 COMPANY SNAPSHOT 148
16.8.2 PRODUCT PORTFOLIO 148
16.8.2.1 RECENT DEVELOPMENTS 148
16.9 IOPTIMA 149
16.9.1 COMPANY SNAPSHOT 149
16.9.2 PRODUCT PORTFOLIO 149
16.9.3 RECENT DEVELOPMENT 149
16.10 MICROSURGICAL TECHNOLOGY. (A SUBSIDIARY OF HALMA PLC) 150
16.10.1 COMPANY SNAPSHOT 150
16.10.2 PRODUCT PORTFOLIO 150
16.10.2.1 RECENT DEVELOPMENT 150
16.11 NEW WORLD MEDICAL, INC. 151
16.11.1 COMPANY SNAPSHOT 151
16.11.2 PRODUCT PORTFOLIO 151
16.11.2.1 RECENT DEVELOPMENTS 151
16.12 NOVA EYE MEDICAL LIMITED 152
16.12.1 COMPANY SNAPSHOT 152
16.12.2 REVENUE ANALYSIS 152
16.12.3 PRODUCT PORTFOLIO 153
16.12.3.1 RECENT DEVELOPMENTS 153
16.13 SIGHT SCIENCES. 154
16.13.1 COMPANY SNAPSHOT 154
16.13.2 REVENUE ANALYSIS 154
16.13.3 PRODUCT PORTFOLIO 155
16.13.3.1 RECENT DEVELOPMENTS 155
17 QUESTIONNAIRE 157
18 RELATED REPORTS 159

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.